U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa
U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process
Pharmaceutical Investing Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Pharmaceutical Investing Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa
Pharmaceutical Investing Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban
Pharmaceutical Investing Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
Biotechnology Stocks on Investors' Radar — Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
American Salars Starts Sampling at 100% Owned Brazilian LCT Pegmatite Project, with Past Samples Hitting 3.72% Li2o and Significant Ree Values
Heritage Mining Announces Encouraging Gold Results from New Millennium Drill Program and provides Exploration Update and Strategic Investment
Quimbaya Gold and Denarius Metals Partner to Formalize Artisanal Mining at Tahami Project, Strengthening Long-Term Exploration Strategy
